Euronext

AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease

Retrieved on: 
Tuesday, November 28, 2023
Euronext, Q&A, CELL, Sickle cell disease, LIVE, Vaccine

AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN SICKLE CELL DISEASE ON THURSDAY NOVEMBER 30, 2023, FROM 3PM TO 4PM CET

Key Points: 
  • AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN SICKLE CELL DISEASE ON THURSDAY NOVEMBER 30, 2023, FROM 3PM TO 4PM CET
    AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease.
  • This live webcast will provide further details on:
    The presentation will be followed by a Q&A session.

Nyxoah Strengthens its Executive Leadership Team

Retrieved on: 
Tuesday, November 28, 2023
DREAM, Mont-Saint-Guibert, Obstructive sleep apnea, FDA, Euronext, Quality, Medtronic, Investment, OSA, PMA, Pharmaceutical industry

Francis will be leading Nyxoah’s Global Regulatory and Quality departments.

Key Points: 
  • Francis will be leading Nyxoah’s Global Regulatory and Quality departments.
  • Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device and life sciences sector.
  • Francis has led Regulatory and Quality departments at Medtronic, Philips, and other companies, including introducing several innovative products and therapies to the market.
  • I am excited having someone with Francis’ regulatory and quality experience joining Nyxoah at this important time, and I look forward to continued investments as we prepare to for a U.S. market entrance,” commented Olivier Taelman, Nyxoah Chief Executive Officer.

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

Retrieved on: 
Tuesday, November 28, 2023
Patient, IWG, Pemphigus, Data, Disease, Conference call, Euronext, Neonatal Fc receptor, ITP, Safety, Nursing

The study did not meet the primary endpoint of a sustained platelet count response in chronic ITP patients.

Key Points: 
  • The study did not meet the primary endpoint of a sustained platelet count response in chronic ITP patients.
  • Additional analyses of the dataset are ongoing and the full results will be presented at an upcoming medical meeting and in a peer-reviewed publication.
  • “We are very grateful to everyone involved in the ADVANCE-SC study, especially the patients and their families, the investigators, and our internal team who worked tirelessly to complete this global study.
  • A webcast of the live call and replay may be accessed on the Investors section of the argenx website.

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

Retrieved on: 
Monday, November 27, 2023
SCD, Database, Polymerization, Recherche, Sickle cell disease, Partnership, Thalassemia, Risk, AP-HP, Death, Hemolytic anemia, Research, B cell, Basophil, VOC, FYN, Assistance, Mortality, Health, Disease, Acute chest syndrome, KIT, RBC, Mouse, Human, Life expectancy, Investment, Euronext, SCIENCE, Inflammation, Patent, Science, CELL, Public, Biomarker, Toxicity, RHU, Histamine, Child, Patient, APHP, Substance P, LYN, ACS, Pharmaceutical industry

THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".

Key Points: 
  • THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".
  • A new patent has been filed, which, if granted, will extend the international protection of masitinib in sickle cell disease until 2040.
  • Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease.
  • There is a significant medical need to prevent the acute and chronic complications of sickle cell disease.

Nyxoah to Participate in the Piper Sandler 35th Annual Healthcare Conference

Retrieved on: 
Tuesday, November 21, 2023
Mont-Saint-Guibert, Piper Sandler Companies, Conference, Obstructive sleep apnea, Fireside, Fireside chats, Euronext, OSA

Mont-Saint-Guibert, Belgium – November 21, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference, which takes place November 28 – 30, 2023 in New York.

Key Points: 
  • Mont-Saint-Guibert, Belgium – November 21, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference, which takes place November 28 – 30, 2023 in New York.
  • Olivier Taelman, Nyxoah’s Chief Executive Officer, will be participating in a Fireside Chat on Wednesday, November 29, 2023, at 2:30pm ET.
  • A webcast of the presentation will be available on the Events section of Nyxoah’s Investor Relations website.
  • Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

Datalogic invests in Oversonic Robotics, continuing its commitment to Artificial Intelligence

Retrieved on: 
Thursday, December 21, 2023
Research and development, Marketing, Attention, Health care, Transport, Robotics, Health, Euronext, Patent, Artificial intelligence, MB, Growth, Entrepreneurship, Safety, Intelligence, Algorithm, Creativity, Environment, Typesetting

BOLOGNA, Italy, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Datalogic S.p.A. (Borsa Italiana S.p.A.: DAL), a company listed on the Euronext STAR Milan of Borsa Italiana S.p.A. and a global leader in automatic data capture and industrial automation markets, announces that through its subsidiary Datalogic S.r.l., it has acquired a minority stake in Oversonic Robotics Srl Benefit Corporation ("Oversonic Robotics"), an innovative software company that develops cognitive computing systems for robotics. Oversonic Robotics has developed RoBee, the first humanoid robot certified to support work in manufacturing facilities of companies with an Industry 5.0 perspective. RoBee can easily perform tasks that could otherwise be detrimental to the health of human workers, both physically and mentally.

Key Points: 
  • Datalogic, a global leader in industrial automation products and solutions, is committed to investing in cutting-edge industrial innovation.
  • In particular, Datalogic and Oversonic Robotics will partner on sales, R&D, and marketing activities.
  • "We are excited to partner with Oversonic Robotics, an Italian company with great experience in creating humanoid robots with artificial intelligence algorithms.
  • Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U.

OTC Markets Group Welcomes d'Amico International Shipping SA to OTCQX

Retrieved on: 
Monday, November 20, 2023
OTCQX, Rail transport by country, DIS, Euronext, Transport, Security (finance)

NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced d'Amico International Shipping SA (Euronext STAR Milan: DIS; OTCQX: DMCOF), an international marine transportation company operating in the product tanker market, has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced d'Amico International Shipping SA (Euronext STAR Milan: DIS; OTCQX: DMCOF), an international marine transportation company operating in the product tanker market, has qualified to trade on the OTCQX® Best Market.
  • d'Amico International Shipping upgraded to OTCQX from the Pink® market.
  • d'Amico International Shipping SA begins trading today on OTCQX under the symbol “DMCOF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
  • Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors.

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

Retrieved on: 
Friday, November 17, 2023
Bulletin, Aleksander Balos, CET, Euronext, Nightclub, Online shopping, ABQ BioPark Aquarium, Cellectis

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Key Points: 
  • NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
  • The notice of meeting as published today in the BALO (Bulletin des Annonces Legales Obligatoires), including the agenda, the text of the resolutions and the terms of participation, is online on the Cellectis website at the following address:

ONWARD® Reports Q3 Business Update and Year-To-Date Highlights

Retrieved on: 
Thursday, November 16, 2023
European Innovation Council, Webcast, PMA, Finger, Gait, Research, Safety, Food, BCI, US Foods, Government, SIX Financial Information, CET, De novo, MJFF, FDA, USD, Movement, Defense, EUR, Rehabilitation, Hemiunu, Euronext, SDVOSB, Hand, ARC, Partnership, Spinal cord, SCI, Nature Medicine, Blood pressure, Medical device, Pharmaceutical industry, Broadcasting, Q3, Zoom

The study participant also received a wireless brain-computer interface (BCI), designed to initiate thought-driven movement when paired with ARC-IM.

Key Points: 
  • The study participant also received a wireless brain-computer interface (BCI), designed to initiate thought-driven movement when paired with ARC-IM.
  • ONWARD ARC-IM delivers targeted, programmed ARC-IM Therapy to the spinal cord to restore movement and other functions after SCI.
  • To date, ARC-IM Therapy has been applied across multiple clinical feasibility studies to restore mobility or stabilize blood pressure after SCI.
  • In September, the Company announced a partnership with Lovell Government Services (Lovell), a Service-Disabled Veteran-Owned Small Business (SDVOSB).

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Retrieved on: 
Thursday, November 16, 2023
Multiple organ dysfunction syndrome, Primary biliary cholangitis, Permeability (electromagnetism), Hepatic encephalopathy, PBC, AASLD, IND, Disease, Mortality, Cirrhosis, Elafibranor, UCSF, Patient, Heart, Liver, ASK1, Caregiver, NTZ, Chronic liver disease, Cell death, MBA, MD, University, Transplant, Doctor of Philosophy, Microbiota, Fibrosis, Ipsen, University of California, European Foundation, Human, Inflammation, Pharmaceutical industry, ACLF, Hyperammonemia, Boston, Euronext

GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.

Key Points: 
  • GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.
  • ACLF is a potentially deadly, but reversible, condition in patients with chronic liver diseases, which is associated with multi-organ failure and high short-term mortality.
  • Pascal Prigent, CEO of GENFIT, commented: “During AASLD we were excited to further discuss our development strategy around our new pipeline focused on ACLF, where we believe multiple programs have the potential to transform the treatment paradigm for these patients.
  • As part of the “ACLF Day” event during AASLD, the critical need for treatment has been highlighted by leading experts in ACLF.